Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ADAP |
---|---|---|
09:32 ET | 82122 | 1.1001 |
09:34 ET | 44973 | 1.11 |
09:36 ET | 76816 | 1.12 |
09:38 ET | 29240 | 1.14 |
09:39 ET | 24353 | 1.1301 |
09:41 ET | 38289 | 1.125 |
09:43 ET | 22038 | 1.1396 |
09:45 ET | 48301 | 1.135 |
09:48 ET | 6611 | 1.14 |
09:50 ET | 17586 | 1.1307 |
09:52 ET | 4631 | 1.1303 |
09:54 ET | 14905 | 1.13 |
09:56 ET | 14545 | 1.1301 |
09:57 ET | 12831 | 1.1314 |
09:59 ET | 12693 | 1.14 |
10:01 ET | 7377 | 1.13 |
10:03 ET | 2791 | 1.13 |
10:06 ET | 850 | 1.1399 |
10:08 ET | 2210 | 1.1385 |
10:10 ET | 7351 | 1.125 |
10:12 ET | 33187 | 1.13 |
10:14 ET | 1717 | 1.1202 |
10:15 ET | 6701 | 1.12 |
10:17 ET | 11759 | 1.125 |
10:19 ET | 4457 | 1.1223 |
10:21 ET | 24666 | 1.1192 |
10:24 ET | 9819 | 1.1104 |
10:26 ET | 10384 | 1.11 |
10:28 ET | 38559 | 1.1 |
10:30 ET | 12439 | 1.1007 |
10:32 ET | 2096 | 1.105 |
10:33 ET | 9792 | 1.1 |
10:35 ET | 3500 | 1.1 |
10:37 ET | 5200 | 1.105 |
10:39 ET | 22538 | 1.1 |
10:42 ET | 3299 | 1.1003 |
10:44 ET | 19255 | 1.1196 |
10:46 ET | 1261 | 1.1101 |
10:48 ET | 1082 | 1.11 |
10:50 ET | 1500 | 1.12 |
10:51 ET | 1103 | 1.1101 |
10:53 ET | 23673 | 1.11 |
10:55 ET | 1735 | 1.1101 |
10:57 ET | 10943 | 1.1 |
11:00 ET | 34000 | 1.11 |
11:02 ET | 200 | 1.105 |
11:06 ET | 3368 | 1.1003 |
11:08 ET | 3600 | 1.105 |
11:09 ET | 1100 | 1.105 |
11:11 ET | 24465 | 1.11 |
11:13 ET | 174 | 1.1102 |
11:15 ET | 200 | 1.1138 |
11:18 ET | 2211 | 1.1101 |
11:20 ET | 4122 | 1.12 |
11:22 ET | 3869 | 1.1107 |
11:24 ET | 4967 | 1.115 |
11:26 ET | 338 | 1.1116 |
11:27 ET | 540 | 1.11 |
11:29 ET | 3700 | 1.11 |
11:31 ET | 100 | 1.11 |
11:33 ET | 3475 | 1.11 |
11:36 ET | 670 | 1.1114 |
11:38 ET | 38291 | 1.108 |
11:40 ET | 900 | 1.1 |
11:42 ET | 5198 | 1.1 |
11:44 ET | 600 | 1.1 |
11:45 ET | 2890 | 1.1 |
11:47 ET | 240 | 1.1 |
11:49 ET | 2814 | 1.105 |
11:51 ET | 2300 | 1.1 |
11:54 ET | 3555 | 1.105 |
11:56 ET | 3772 | 1.109 |
11:58 ET | 1389 | 1.1 |
12:00 ET | 2484 | 1.1004 |
12:02 ET | 2569 | 1.1019 |
12:03 ET | 5204 | 1.105 |
12:05 ET | 3300 | 1.1 |
12:07 ET | 136 | 1.1002 |
12:09 ET | 553 | 1.1096 |
12:12 ET | 1250 | 1.105 |
12:14 ET | 301 | 1.1004 |
12:16 ET | 500 | 1.1096 |
12:18 ET | 16572 | 1.1 |
12:20 ET | 1255 | 1.1 |
12:21 ET | 1287 | 1.105 |
12:23 ET | 2247 | 1.1093 |
12:27 ET | 1526 | 1.1088 |
12:30 ET | 100 | 1.11 |
12:32 ET | 562 | 1.1004 |
12:34 ET | 650 | 1.1 |
12:36 ET | 4758 | 1.1 |
12:38 ET | 4200 | 1.101 |
12:39 ET | 1789 | 1.095 |
12:41 ET | 5000 | 1.091 |
12:43 ET | 11720 | 1.1 |
12:45 ET | 71093 | 1.09 |
12:48 ET | 3857 | 1.085 |
12:50 ET | 31444 | 1.09 |
12:52 ET | 10777 | 1.085 |
12:54 ET | 2700 | 1.0801 |
12:56 ET | 5100 | 1.09 |
12:57 ET | 962 | 1.09 |
12:59 ET | 2355 | 1.09 |
01:03 ET | 1000 | 1.0897 |
01:06 ET | 7490 | 1.085 |
01:08 ET | 800 | 1.085 |
01:10 ET | 28082 | 1.09 |
01:12 ET | 10073 | 1.09 |
01:14 ET | 430 | 1.0898 |
01:15 ET | 12588 | 1.095 |
01:17 ET | 228 | 1.098 |
01:19 ET | 1978 | 1.092 |
01:21 ET | 1464 | 1.0904 |
01:24 ET | 360 | 1.0917 |
01:26 ET | 35610 | 1.085 |
01:28 ET | 3164 | 1.08 |
01:30 ET | 800 | 1.09 |
01:32 ET | 1156 | 1.085 |
01:33 ET | 500 | 1.09 |
01:35 ET | 1000 | 1.0887 |
01:37 ET | 9524 | 1.09 |
01:39 ET | 250 | 1.095 |
01:42 ET | 387 | 1.09 |
01:44 ET | 300 | 1.0909 |
01:46 ET | 3932 | 1.09 |
01:48 ET | 1100 | 1.09 |
01:50 ET | 1005 | 1.0901 |
01:51 ET | 15618 | 1.1 |
01:53 ET | 3400 | 1.0901 |
01:55 ET | 378 | 1.1 |
01:57 ET | 2000 | 1.095 |
02:00 ET | 1172 | 1.095 |
02:02 ET | 3200 | 1.09 |
02:04 ET | 600 | 1.095 |
02:06 ET | 546 | 1.095 |
02:08 ET | 316 | 1.1 |
02:09 ET | 20378 | 1.095 |
02:11 ET | 1185 | 1.1 |
02:13 ET | 6300 | 1.095 |
02:15 ET | 400 | 1.0917 |
02:18 ET | 15671 | 1.085 |
02:20 ET | 4473 | 1.0896 |
02:22 ET | 1931 | 1.0802 |
02:24 ET | 184 | 1.085 |
02:26 ET | 1300 | 1.0899 |
02:29 ET | 87164 | 1.0815 |
02:31 ET | 14373 | 1.08 |
02:36 ET | 500 | 1.0852 |
02:38 ET | 10200 | 1.08 |
02:40 ET | 788 | 1.0801 |
02:42 ET | 591 | 1.0821 |
02:44 ET | 2900 | 1.084 |
02:45 ET | 7300 | 1.0879 |
02:47 ET | 1637 | 1.085 |
02:49 ET | 7500 | 1.08 |
02:51 ET | 47220 | 1.08 |
02:54 ET | 18470 | 1.0801 |
02:56 ET | 37890 | 1.08 |
02:58 ET | 36863 | 1.07 |
03:00 ET | 13327 | 1.06 |
03:02 ET | 3668 | 1.065 |
03:03 ET | 4075 | 1.06 |
03:05 ET | 3500 | 1.06 |
03:07 ET | 5083 | 1.06 |
03:09 ET | 16544 | 1.065 |
03:12 ET | 30949 | 1.0501 |
03:14 ET | 20948 | 1.0696 |
03:16 ET | 151 | 1.0696 |
03:18 ET | 17771 | 1.062 |
03:20 ET | 3576 | 1.07 |
03:21 ET | 5501 | 1.07 |
03:23 ET | 20780 | 1.0798 |
03:25 ET | 10200 | 1.075 |
03:27 ET | 18155 | 1.075 |
03:30 ET | 652 | 1.075 |
03:32 ET | 2143 | 1.07 |
03:34 ET | 12953 | 1.07 |
03:36 ET | 18983 | 1.06 |
03:38 ET | 1504 | 1.06 |
03:39 ET | 1300 | 1.065 |
03:41 ET | 2012 | 1.06 |
03:43 ET | 650 | 1.06 |
03:45 ET | 5154 | 1.065 |
03:48 ET | 21003 | 1.06 |
03:50 ET | 14590 | 1.06 |
03:52 ET | 53725 | 1.075 |
03:54 ET | 2053 | 1.07 |
03:56 ET | 5195 | 1.08 |
03:57 ET | 9023 | 1.08 |
03:59 ET | 19374 | 1.07 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Adaptimmune Therapeutics PLC | 288.8M | -1.5x | --- |
Poseida Therapeutics Inc | 289.9M | -2.6x | --- |
MacroGenics Inc | 256.2M | -11.9x | --- |
Innate Pharma SA | 221.6M | -26.1x | --- |
ADC Therapeutics SA | 329.9M | -1.2x | --- |
AVITA Medical Inc | 247.9M | -5.2x | --- |
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that provides a treatment option for people with synovial sarcoma. The Company is in the process of transitioning lete-cel, which targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). Its clinical pipeline includes SURPASS-III Phase II Trial with ADP-A2M4CD8 and SURPASS Phase I Trial with ADP-A2M4CD8. The Company’s most advanced pre-clinical programs are for T-cell therapies directed to the PRAME target (ADP-600) and to CD70 (ADP-520). ADAP-600 is an engineered TCR T-cell.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $288.8M |
---|---|
Revenue (TTM) | $18.4M |
Shares Outstanding | 255.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.33 |
EPS | $-0.73 |
Book Value | $0.17 |
P/E Ratio | -1.5x |
Price/Sales (TTM) | 15.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -918.45% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.